Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CASP1 | P29466 | 1/20 | 0.66 |
| ▸ | CASP7 | P55210 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262908 | 0.87 | KDM4E (0.62) | KDM4EALDH1A1FOLH1GAAMAPT | |
| SCHEMBL9449744 | 0.87 | KDM4E (0.63) | KDM4EALDH1A1FOLH1GAAMAPT | |
| SCHEMBL3069354 | 0.87 | KDM4E (0.68) | KDM4EALDH1A1FOLH1HTTHSD17B10 | |
| SCHEMBL13701155 | 0.86 | KDM4E (0.71) | KDM4EALDH1A1FOLH1HTTHSD17B10 | |
| SCHEMBL4257382 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1FOLH1GAAMAPT | |
| SCHEMBL5002301 | 0.85 | KDM4E (0.61) | KDM4EALDH1A1FOLH1HTTHSD17B10 | |
| SCHEMBL29621784 | 0.84 | KDM4E (0.69) | KDM4EALDH1A1FOLH1HTTHSD17B10 | |
| SCHEMBL3205801 | 0.84 | KDM4E (0.69) | KDM4EALDH1A1FOLH1HTTHSD17B10 | |
| SCHEMBL7823003 | 0.84 | KDM4E (0.63) | KDM4EALDH1A1FOLH1GAAMAPT | |
| SCHEMBL9188195 | 0.83 | KDM4E (1.00) | KDM4EALDH1A1FOLH1EGFRMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098895-B1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI SYNTHELABO (FR) | 2002-06-05 | — | — | EP | claimed |
| US-6365748-B1 | BY TREATING 2-((4-(2-CHLOROPHENYL)-2-THIAZOLYL)CARBAMOYL) INDOLE-1-ACETIC ACID OR ITS ESTERS WITH POTASSIUM CARBONATE IN A TWO PHASE SOLVENT SYSTEM,OF A MIXTURE OF WATER AND A SLIGHTLY IMMISCIBIBLE SOLVENT; INJECTIBLE CHOLECYSTOKININ | SANDOFI-SYNTHELABO (FR) | 2002-04-02 | — | — | US | claimed |
| EP-1098895-A1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI-SYNTHELABO (FR) | 2001-05-16 | — | — | EP | claimed |
| WO-2000005233-A1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI-SYNTHELABO (FR) | 2000-02-03 | — | — | WO | claimed |
| US-5229413-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | claimed |
| EP-0396124-A2 | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | G.D. Searle & Co. (US) | 1990-11-07 | — | — | EP | claimed |
| JP-3047123-A | — | — | None | — | — | JP | disclosed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| CN-111386107-A | Use of probenecid in the treatment of an epileptic disease, disorder or condition | 巴黎科技与文学─拉丁区 | 2020-07-07 | — | — | CN | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-04-01 | — | — | US | disclosed |
| EP-1098895-A1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI-SYNTHELABO (FR) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000005233-A1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI-SYNTHELABO (FR) | 2000-02-03 | — | — | WO | disclosed |
| US-5229413-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5137910-A | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | C.D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
| JP-H0347123-A | CNS DISEASE THERAPEUTIC COMPOSITION CONTAINING INDOLE-2-CARBOXYLATE COMPOUND | G D SEARLE & CO | 1991-02-28 | — | — | JP | disclosed |
| EP-0396124-A2 | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | G.D. Searle & Co. (US) | 1990-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | KDM4E 4411/4885ALDH1A1 528/4885FOLH1 757/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | KDM4E 4411/4885ALDH1A1 528/4885FOLH1 757/4885 |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | HMOX1, HMOX2, PPOX | KDM4E 2274/4885ALDH1A1 802/4885FOLH1 931/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | KDM4E 4411/4885ALDH1A1 528/4885FOLH1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.